Profile banner
Kelvin C. Mo

Kelvin C. Mo

Computational immunology researcher focused on CAR T-cell therapy

Stanford, California
stanford
Favicon imagemed.stanford.edu
Favicon imagemcb.berkeley.edu
Favicon imageorcid.org

Summary

Bridges computational and experimental immunology: Kelvin combines training in molecular biology and data science to develop computational tools and predictive models that analyze high-dimensional single-cell and spatial transcriptomics data to study CAR T-cell therapy response and resistance mechanisms. stanford+2
Active contributor to collaborative, multi-author translational research: He is a co-author on multiomic single-cell studies and conference abstracts (Blood / ASH) investigating tumor microenvironment features linked to CAR T therapy outcomes, indicating experience in large-team, clinically-relevant research projects. ashpublications+1
Trained across academia and industry: Kelvin has undergraduate research and project experience at UC San Diego (including iGEM), internships at biotech and pharma companies, and data-science experience at Intel, reflecting interdisciplinary skills spanning biology, computation, and industry-facing development. igem+2
Focus on interpretable, regulatory-prior informed machine learning for single-cell prediction: Contributions to methods (e.g., tcellMIL) emphasize using gene regulatory network features and attention-based MIL to improve generalization and interpretability in predicting patient-level outcomes from single-cell data. neurips+1

Work

Education

Projects

Writing

Patient-level prediction from single-cell data using attention-based multiple instance learning with regulatory priors (tcellMIL)

January 1, 2025

Describes tcellMIL, an attention-based multiple instance learning framework using regulon activity priors to predict patient-level outcomes from single-cell data and identify outcome-relevant subpopulations; applied to CAR T infusion products.

Favicon imageneurips.cc

CCL8/CCL13-Producing Tumor-Associated Macrophages Linked to Poor Outcomes after CAR T Cell Therapy for LBCL

November 1, 2024

Oral abstract reporting multi-omic single-cell analyses that implicate CCL8/CCL13-producing tumor-associated macrophages in poor outcomes after CAR T cell therapy for large B-cell lymphoma (LBCL); includes single-cell interactome and deconvolution analyses validating associations with treatment resistance.

Favicon imageashpublications.org

CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

November 1, 2024

Multiomic single-cell study identifying transcriptional and epigenetic features in CAR22 products and expanding CAR22 cells associated with IEC-HS, highlighting interferon-stimulated genes, STAT2 activity, and chromatin accessibility signatures.

Favicon imagesemanticscholar.org